Cardiotoxicity associated with targeting kinase pathways in cancer.
about
Getting to the Heart of the Matter: An Overview of Cardiac Toxicity Related to Cancer TherapyComputer-based prediction of the drug proarrhythmic effect: problems, issues, known and suspected challengesMito-tempol and dexrazoxane exhibit cardioprotective and chemotherapeutic effects through specific protein oxidation and autophagy in a syngeneic breast tumor preclinical modelLeucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasisDrug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trialsUse of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs) to Monitor Compound Effects on Cardiac Myocyte Signaling Pathways.Cardiac imaging approaches to evaluate drug-induced myocardial dysfunctionRecent advances in antimultiple myeloma drug development.Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.Multi-marker Solid Tumor Panels Using Next-generation Sequencing to Direct Molecularly Targeted Therapies.A RTK-based functional RNAi screen reveals determinants of PTX-3 expression.Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injuryAutomatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS)Biomaterial based cardiac tissue engineering and its applicationsLarge-scale automatic extraction of side effects associated with targeted anticancer drugs from full-text oncological articles.Experience with sunitinib in the treatment of metastatic renal cell carcinomaA Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate.tcTKB: an integrated cardiovascular toxicity knowledge base for targeted cancer drugs.Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity.Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinaseGenetic basis for the increased expression of vacuolar H+ translocating ATPase genes upon imatinib treatment in human lymphoblastoid cells.Signaling through the vascular endothelial growth factor receptor VEGFR-2 protects hippocampal neurons from mitochondrial dysfunction and oxidative stress.Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma.Drug induced rhabdomyolysis.Insights from Pim1 structure for anti-cancer drug design.Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).Cardiovascular safety and hemodynamic considerations in oncology drug development - webinar highlights October 10th 2012.Canonical and new generation anticancer drugs also target energy metabolism.Cardiotoxicity of antineoplastic agents: what is the present and future role for imaging?Human stem cell-derived cardiomyocytes in cellular impedance assays: bringing cardiotoxicity screening to the front line.Cancer chemotherapy and cardiac arrhythmias: a review.Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management.Safety issues of compounds acting on adenosinergic signalling.Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics.From the Cover: High-Throughput Imaging of Cardiac Microtissues for the Assessment of Cardiac Contraction during Drug Discovery.Protein Quality Control Dysfunction in Cardiovascular Complications Induced by Anti-Cancer Drugs.Phenotypic profiling of structural cardiotoxins in vitro reveals dependency on multiple mechanisms of toxicity.The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs.Cardiac Non-myocyte Cells Show Enhanced Pharmacological Function Suggestive of Contractile Maturity in Stem Cell Derived Cardiomyocyte Microtissues.Enhanced characterization of contractility in cardiomyocytes during early drug safety assessment.
P2860
Q26797138-D9FA133B-12A6-41C2-BBE6-B041F8DA2BFCQ26861453-DB1F016D-2D51-49D8-8ECA-CE7F544EDB70Q27310238-5C6B75F6-8B41-4E1B-896C-04B7706CE42CQ27315276-AD3E2104-C8B2-46C9-9C9A-AE7C689A3D23Q28071256-A0E10A56-A728-4208-A9C1-9872EEFC184DQ30402943-25F39114-0263-4957-A6CD-29E53DE4E39EQ30446453-EBD3458F-D3D8-469D-8E02-A06082DC5600Q33416297-2E3F5B60-E89F-4325-AEC5-FD819D37F742Q33573760-C58CD728-80E8-4839-922C-D4A7942E526AQ33686447-4B77B29D-5643-45D8-A7BF-7CD57EF2117AQ34662196-A352F2DE-A8A2-43EE-B269-C5FD3172A395Q35039202-97E7A88D-CD3D-4D41-B246-7D0A55AA8342Q35673776-68A62148-FB13-45C8-A95E-030C090694DFQ35731251-55B97064-9D36-45FA-97BA-2599FCD3639DQ36092046-8FBBF3F8-FC94-4346-893B-2E6B8E87C50DQ36231729-801F12C5-BF0C-4A03-B62F-F850E5A04C97Q36262416-29DFDE6F-43DC-4E81-A669-63FE4F8A6E94Q36613254-87FAC920-50A3-4126-A4EE-3B730731AD50Q36637796-BB427D39-645B-4B44-88A5-3221AFDA450CQ36694985-D5DC65C4-8D8E-466E-83FF-0844781283F0Q36721667-C7E3AFB8-B80A-40DD-ADBF-D7FCA97FA612Q37130181-5C1ACF36-48A3-4A57-B7CA-6999320BC800Q37274320-A386EDCF-F8C5-443D-B097-DFBFC70D47CEQ38007737-9F5BB2ED-9AB6-4CF7-9FB7-B0639E16425AQ38045948-CA0EB527-0138-4817-9B54-BDF10312EBEAQ38101883-1B5176FD-9F7B-4581-9F6F-D8F607396C5BQ38104812-F130D295-050B-4825-BE52-B80336F71072Q38208982-2A43A9BF-3E57-4220-9BF2-6FF0E93194FFQ38225977-600743FF-CFD9-4894-8CF1-79D4AD49111EQ38240972-ECA1367A-E3C3-4881-80CB-F64356005949Q38313870-498486F9-15C6-43B1-8079-A8852A2BB77EQ38551764-AE72BAB5-1925-4505-AFBE-64AD8157AE0DQ38843185-1B2DE06C-1D5C-41A1-B095-6599898E7021Q39014995-A775176C-AD7C-479D-978E-18DC2BA85698Q39030459-A7C4BA1C-C83E-4261-9E18-7636FFE8D266Q39102231-C0DC13DB-70BE-42B4-B0D5-9456ACE1A085Q39211305-3B9ECC9E-385E-4975-A9FE-B0BD3A83C565Q39231153-F13DB1EB-3F59-4642-9A07-A10ACBA93963Q39812568-E64FBDE5-CF4A-4170-851A-0AA628D691DEQ41144260-8958E4DF-33B8-4CB1-9C0F-77939D5C1588
P2860
Cardiotoxicity associated with targeting kinase pathways in cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cardiotoxicity associated with targeting kinase pathways in cancer.
@en
Cardiotoxicity associated with targeting kinase pathways in cancer.
@nl
type
label
Cardiotoxicity associated with targeting kinase pathways in cancer.
@en
Cardiotoxicity associated with targeting kinase pathways in cancer.
@nl
prefLabel
Cardiotoxicity associated with targeting kinase pathways in cancer.
@en
Cardiotoxicity associated with targeting kinase pathways in cancer.
@nl
P2093
P2860
P356
P1476
Cardiotoxicity associated with targeting kinase pathways in cancer.
@en
P2093
Alex R Bell
Howard R Mellor
Jean-Pierre Valentin
Ruth R A Roberts
P2860
P356
10.1093/TOXSCI/KFQ378
P577
2010-12-22T00:00:00Z